ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / TLX / insiders
IDYA (34) BHC (68) DYN (26) ELVN (39) ⌘ Pro Terminal →

Telix Pharmaceuticals Limited (TLX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$9.05 -0.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.02

Telix Pharmaceuticals Limited (TLX) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $3.08B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TLX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Telix Pharmaceuticals Limited (NASDAQ: TLX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $9.05 (-0.55% 1D, market cap $3.08B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TLX ranks #300 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TLX compare to IDYA and BHC in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TLX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IDYA (IDEAYA Biosciences Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -13.8%, cap $3.08B) and BHC (Bausch Health Companies Inc.) posts a C+ grade (68/100 RQD, P/E 21.2x, ROIC 7.6%, cap $3.07B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TLX?
▼

For Telix Pharmaceuticals Limited (TLX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #300 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.02 (-0.29%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 2.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (12)Whales (5)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$14 Bull$9 Base$7 Bear
📬 FREE TLX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TLX)Realized 20D OHLCV Swing Band: ±4.3%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY TLX SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 2.2% FCF Margin ($86.3M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
55
Grade C$10.92+2.2% Next Q
Q2 (-2Q)
52
Grade C-$11.16-19.1% Next Q
Q3 (-1Q)
50
Grade C-$9.03+0.2% Next Q
Current
47
Grade D$9.05-5.9% Hist 90D α
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TLX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TLX currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.97) and Max Pain ($9.50) forces dealer call-delta covering toward $13.77.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TLX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TLX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

TLX Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (TLX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on TLX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TLX)

  • ✓Walkthrough of TLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.83%🛡️ HOLDING TREND SUPPORT
2026-11-03O $9.51H $9.51L $9.05C $9.05VOL 341.9K
RES: $13.73SUP: $8.84SMA50: $10.97SMA200: $9.92
$13.42$12.14$10.86$9.57$8.29RES $13.73SUP $8.84$9.052026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TLX Butterfly Map → + Track TLX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TLX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TLX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TLX)

Health Care Rank #300 of 1015 ⚔️ IDYA vs TLX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TLX vs. IDYA, BHC, DYN, ELVN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Telix Pharmaceuticals Limited (TLX) ranks #300 by composite RQD confidence (47/100, grade D) and #202 by equity capitalization ($3.08B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with TLX at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TLX ACTIVE
Telix Pharmaceuticals Limited
D 47/100 — — — -0.55% $3.08B Benchmark Subject
IDYA
IDEAYA Biosciences Inc.
E 34/100 — — -13.8% -1.00% $3.08B /idya-vs-tlx →
BHC
Bausch Health Companies Inc.
C+ 68/100 21.2x — 7.6% -2.19% $3.07B /bhc-vs-tlx →
DYN
Dyne Therapeutics Inc.
E 26/100 — — -35.0% +3.66% $3.12B /dyn-vs-tlx →
ELVN
Enliven Therapeutics Inc.
D- 39/100 — — -26.2% +0.86% $3.24B /elvn-vs-tlx →

2. TLX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Telix Pharmaceuticals Limited (TLX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $3.08B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. TLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Telix Pharmaceuticals Limited (NASDAQ: TLX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $9.05 (-0.55% 1D, market cap $3.08B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TLX ranks #300 in composite RQD confidence.

How does TLX compare to IDYA and BHC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TLX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IDYA (IDEAYA Biosciences Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -13.8%, cap $3.08B) and BHC (Bausch Health Companies Inc.) posts a C+ grade (68/100 RQD, P/E 21.2x, ROIC 7.6%, cap $3.07B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TLX?

For Telix Pharmaceuticals Limited (TLX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #300 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TLX trading relative to its 50-day, 200-day, and 52-week technical levels?

TLX last traded at $9.05 (-0.55% on volume of 258,175 shares), positioning the stock -17.50% below its 50-day simple moving average ($10.97) and -8.77% below its 200-day simple moving average ($9.92). Across its 52-week range of $6.28 to $13.11, TLX sits at the 40.6% percentile with a 14-day RSI of 37.4 (NEUTRAL RANGE) and an implied next-earnings move of ±4.3% ($8.66 to $9.44).

Direct Sub-Reports: TLX RQD Cockpit TLX 12M Forecast TLX Earnings & Move TLX Dividends & DRIP TLX Insiders & 13F TLX Whale Options TLX Profit Sankey TLX News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

TLX — Telix Pharmaceuticals Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Telix Pharmaceuticals Limited (TLX) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $9.05 (-0.55% 1D, market capitalization $3.08B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Telix Pharmaceuticals Limited (TLX) is a NASDAQ-listed operating company in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity market capitalization of $3.08B. The business operates with a gross margin of 0%, an operating margin of 0%, and a return on invested capital (ROIC) of 0% (free cash flow yield of 0%). Within the Biotechnology: Pharmaceutical Preparations peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $6.28 – $13.11 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), TLX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can TLX sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $13.11 52-week high?
  • Key Question #3: How sensitive is TLX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TLX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Telix Pharmaceuticals Limited (TLX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TLX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TLX Bull vs. Bear Conversation Board — What's Your Call at $9.05?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TLX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TLX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $11.56 (+27.0%)
📌 Pinned Debate

The forensic balance sheet pillar scores 13 / 20 with a Piotroski F of 6/9 and Debt/Equity of 0.5, and the 52-week range shows the pric

The forensic balance sheet pillar scores 13 / 20 with a Piotroski F of 6/9 and Debt/Equity of 0.5, and the 52-week range shows the price at 9.51 versus a $13.11 high.. When you look under the hood at TLX, Fundamental Cash Engine is 12/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $13.11. My 12M target is $11.56.

CapAlloc_Nerd 🐂 BULL

@MidwestValue Agree on the RQD 47/100 quality, though with 1.0 beta I'm scaling in with half-size at $9.10 and keeping dry powder in case we test $8.46.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $6.92 (-24.0%)
Spot @ $9.10

Whale 13F Flow scores only 5 / 20 and the cash-engine metrics (ROIC 0%, FCF yield 0%) show no current cash-return support, with a RED-f

Here is the bear case nobody on the bull side wants to address on TLX: Whale 13F Flow scores only 5 / 20 and the cash-engine metrics (ROIC 0%, FCF yield 0%) show no current cash-return support, with a RED-flagged 12-month price target cut to $17.95.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE